Cambridge Cognition announces new major pharma client for schizophrenia clinical trials

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has been awarded contracts for two clinical trials by a top 20 pharmaceutical company to assess the pro-cognitive effects of a new drug in schizophrenia. Together the contracts are worth £700,000 over two years. This is the second pharmaceutical client to award Cambridge Cognition major contracts for cognitive assessments for schizophrenia in the last year1. Approximately 30 clinical trials on new drugs for schizophrenia run every year2, demonstrating the potential for further sales in this therapeutic area.

Cambridge Cognition offers cognitive assessments with the sensitivity to measure the distinct cognitive processes impaired in schizophrenia, including memory, attention and executive function. Between September 2020 and December 2021, the Company was contracted for six pivotal trials for another client’s new schizophrenia drug1, earning Cambridge Cognition a reputation in the field for delivering highly sensitive cognitive assessments. Now, this new client, a top 20 pharmaceutical company has contracted Cambridge Cognition to determine the efficacy of its new drug for improving cognition in patients with schizophrenia and another indication. Cambridge Cognition will provide its proprietary cognitive assessments (CANTABTM), its electronic questionnaires and scales platform (eCOA), and specialist, study management services.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“It is excellent news that we have secured another top 20 pharmaceutical company as a new client and that we are conducting more clinical trials for patients with schizophrenia, which is a therapeutic area we are targeting for growth.  We are pleased with this client win which continues the very positive momentum in the business and further improves our revenue visibility.”

1.     Announced by the Company on 1 September 2020, 30 March 2021, 26 October 2021 and 9 December 2021

2.     TrialTrove search of industry sponsored PhII – IV Schizophrenia Trials 2011 – 2021

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions